A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

Condition:   HER2-negative Metastatic Breast Cancer Interventions:   Drug: DAN-222;   Drug: Niraparib Sponsor:   Dantari, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials